Historique de carrière de J. Henri Bayle
Anciens postes connus de J. Henri Bayle
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| BELLICUM PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | 01/01/2014 | 01/03/2023 |
Formation de J. Henri Bayle
| Princeton University | Doctorate Degree |
| University of Alberta | Undergraduate Degree |
Statistiques
Internationale
| Etats-Unis | 3 |
| Canada | 2 |
Opérationnelle
| Chief Tech/Sci/R&D Officer | 1 |
| Doctorate Degree | 1 |
| Undergraduate Degree | 1 |
Sectorielle
| Consumer Services | 3 |
| Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Bellicum Pharmaceuticals, Inc.
 Bellicum Pharmaceuticals, Inc. BiotechnologyHealth Technology Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. Its product candidates include BPX-601, BPX-603, and Rivo-cel (rivogenlecleucel, formerly known as BPX-501). The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX. | Health Technology |
- Bourse
- Insiders
- J. Henri Bayle
- Expérience
